Coya Therapeutics, INC

Coya Therapeutics stockholders re-elected two Class I directors and ratified the appointment of their independent auditor.

Coya Therapeutics has entered into a Sales Agreement with Leerink Partners to offer and sell up to $30 million of its common stock.

Coya Therapeutics reports Q1 2026 financial results, highlights FDA Fast Track Designation for COYA 302 for ALS, and provides corporate and pipeline updates.

Coya Therapeutics founder Dr. Howard Berman steps down as Executive Chairman, with industry veteran Mark H. Pavao appointed as an independent director.

Coya Therapeutics announced its fiscal year 2025 financial results and provided a corporate update highlighting significant progress in its clinical programs and strengthened financial position.

Coya Therapeutics announced an $11.1 million private placement led by Dr. Reddys Laboratories and Greenlight Capital to fund commercial readiness for COYA 302.

Coya Therapeutics reports a decrease in R&D expenses and an increase in G&A for Q1 2026, with cash reserves projected to last into the second half of 2027.

Coya Therapeutics reported progress on its lead ALS drug candidate, COYA 302, with FDA IND acceptance and a $4.2 million milestone payment, alongside a post-period $23 million public offering.

Coya Therapeutics reported increased net losses and a significant delay in FDA approval for its COYA 302 ALS treatment IND application, impacting its financial outlook.

Coya Therapeutics' Q1 2025 results show increased R&D spending and a widening net loss, driven by the advancement of COYA 302 and expansion of the investigational pipeline.

Coya Therapeutics reported a net loss of $4.0 million for Q3 2024, while advancing its pipeline and securing additional funding.

Coya Therapeutics reports a net loss of $7.9 million for the first six months of 2024, while advancing its pipeline and securing additional funding.

Coya Therapeutics, a clinical-stage biotech, reported a $21.2 million net loss for 2025 while advancing its lead asset COYA 302 into Phase 2 for ALS and receiving IND acceptance for FTD, supported by a recent $11.1 million financing.

Coya Therapeutics files an amendment to its annual report on Form 10-K/A to include previously omitted Part III information and updated certifications.

Coya Therapeutics, a clinical-stage biotechnology company, announces its 10-K filing, highlighting pipeline expansion and financial results for the year ended December 31, 2024.

Coya Therapeutics has partnered with Dr. Reddy's for the development and commercialization of COYA 302 in key markets, while also securing significant funding through a private placement.

Coya Therapeutics, Inc. director Mark H. Pavao acquired 10,000 stock options with an exercise price of $4.53, vesting over one year.

Coya Therapeutics' Chief Financial Officer, David S. Snyder, was granted 140,041 stock options with an exercise price of $4.73, vesting over 36 months.

Coya Therapeutics' Chief Medical Officer, Fred Grossman, was granted 140,041 stock options with an exercise price of $4.73, vesting over 36 months.

Coya Therapeutics, Inc. has granted its Executive Chairman, Howard Berman, 15,257 stock options with an exercise price of $4.73, vesting over 36 months.

Coya Therapeutics' CEO, Arun Swaminathan, was granted 293,983 stock options with an exercise price of $4.73, vesting over 36 months.

Anabella Villalobos, a Director at Coya Therapeutics, Inc., was granted 10,000 stock options with an exercise price of $5.65, vesting on January 2, 2027.

Coya Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 25, 2026, to elect directors and ratify auditors.

Coya Therapeutics will hold its annual stockholder meeting virtually on June 26, 2025, to vote on the election of directors and the ratification of its accounting firm.

Coya Therapeutics will hold its annual stockholders meeting virtually on June 26, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Coya Therapeutics is holding its annual meeting to elect directors, approve an amendment to its equity incentive plan, and ratify its accounting firm.

Coya Therapeutics announces its annual stockholder meeting to be held virtually on May 8, 2024, featuring proposals including director elections and an amendment to the equity incentive plan.

Coya Therapeutics is asking stockholders to approve an amendment to its 2021 Equity Incentive Plan to increase the number of shares available for issuance by 750,000, aiming to attract and retain key talent.

A Schedule 13G filing reveals Orin Hirschman and AIGH Capital Management LLC's beneficial ownership of Coya Therapeutics, Inc. common stock.

Dr. Reddy's Laboratories, Inc. and its parent entities have disclosed a 9.7% passive beneficial ownership stake in Coya Therapeutics, Inc.

The Vanguard Group has filed an amended Schedule 13G, disclosing its beneficial ownership in Coya Therapeutics Inc. has fallen to 4.29% following an internal realignment.

AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, disclosing beneficial ownership in Coya Therapeutics, Inc. common stock.

Affiliates of Greenlight Capital, including David Einhorn, have disclosed a 9.9% beneficial ownership stake in Coya Therapeutics, Inc. as of December 31, 2024, according to a recent Schedule 13G/A filing.

AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, disclosing their combined passive beneficial ownership of 8% of Coya Therapeutics, Inc.'s common stock as of December 31, 2024.